[Skip to Navigation]
Sign In
Correction
September 15, 2021

Errors in Figure 2, Figure 3, and the Supplement

JAMA Netw Open. 2021;4(9):e2130836. doi:10.1001/jamanetworkopen.2021.30836

In the Original Investigation titled “Oral Anticoagulants for Nonvalvular Atrial Fibrillation in Patients With High Risk of Gastrointestinal Bleeding,”1 published August 16, 2021, there were errors in Figure 2, Figure 3, and the Supplement. In Figure 2, the P value for ischemic stroke in the comparison of rivaroxaban vs warfarin should have read .001. In Figure 3, the number of events in the reference group for major bleeding in the comparison of apixaban vs dabigatran should have read 599; the final comparison should have been dabigatran vs rivaroxaban; and the hazard ratio for ischemic stroke in the comparison of dabigatran vs rivaroxaban should have read 1.18. The Supplement has also been updated with new versions of eTable 2 and eFigure 2. This article has been corrected.1

References
1.
Lip  GYH, Keshishian  AV, Zhang  Y,  et al.  Oral anticoagulants for nonvalvular atrial fibrillation in patients with high risk of gastrointestinal bleeding.   JAMA Netw Open. 2021;4(8):e2120064. doi:10.1001/jamanetworkopen.2021.20064PubMedGoogle Scholar
×